Assembly Biosciences Inc
ASMB24.460USD
+2.190+9.83%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
187.66MValor de mercado
PerdaP/L TTM
Mais detalhes de Assembly Biosciences Inc Empresa
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Informações da empresa
Código da empresaASMB
Nome da EmpresaAssembly Biosciences Inc
Data de listagemDec 17, 2010
CEO- -
Número de funcionários73
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 17
EndereçoTwo Tower Place
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone18334094583
Sitehttps://www.assemblybio.com/
Código da empresaASMB
Data de listagemDec 17, 2010
CEO- -
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John G. McHutchison, M.D.
Dr. John G. McHutchison, M.D.
Director
Director
16.60K
+18.30%
Mr. Jason A. Okazaki
Mr. Jason A. Okazaki
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
14.11K
+55.95%
Dr. Nicole S. White, Ph.D.
Dr. Nicole S. White, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
7.82K
+78.83%
Sir Michael Houghton, Esq.
Sir Michael Houghton, Esq.
Independent Director
Independent Director
3.20K
--
Mr. Anthony E. (Tony) Altig
Mr. Anthony E. (Tony) Altig
Independent Director
Independent Director
666.00
--
Ms. Jeanette Bjorkquist
Ms. Jeanette Bjorkquist
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Ms. Gina Consylman, CPA
Ms. Gina Consylman, CPA
Independent Director
Independent Director
--
--
Dr. Tomas Cihlar, Ph.D.
Dr. Tomas Cihlar, Ph.D.
Director
Director
--
--
Mr. Robert D. Cook, II
Mr. Robert D. Cook, II
Director
Director
--
--
Dr. William E. Delaney, IV, Ph.D.
Dr. William E. Delaney, IV, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. John G. McHutchison, M.D.
Dr. John G. McHutchison, M.D.
Director
Director
16.60K
+18.30%
Mr. Jason A. Okazaki
Mr. Jason A. Okazaki
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
14.11K
+55.95%
Dr. Nicole S. White, Ph.D.
Dr. Nicole S. White, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
7.82K
+78.83%
Sir Michael Houghton, Esq.
Sir Michael Houghton, Esq.
Independent Director
Independent Director
3.20K
--
Mr. Anthony E. (Tony) Altig
Mr. Anthony E. (Tony) Altig
Independent Director
Independent Director
666.00
--
Ms. Jeanette Bjorkquist
Ms. Jeanette Bjorkquist
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Gilead Sciences Inc
33.97%
Farallon Capital Management, L.L.C.
8.60%
Commodore Capital LP
7.54%
Schornstein (Alexander)
4.10%
The Vanguard Group, Inc.
1.91%
Outro
43.88%
Investidores
Investidores
Proporção
Gilead Sciences Inc
33.97%
Farallon Capital Management, L.L.C.
8.60%
Commodore Capital LP
7.54%
Schornstein (Alexander)
4.10%
The Vanguard Group, Inc.
1.91%
Outro
43.88%
Tipos de investidores
Investidores
Proporção
Corporation
33.97%
Hedge Fund
17.33%
Investment Advisor
4.70%
Individual Investor
4.58%
Investment Advisor/Hedge Fund
1.21%
Research Firm
0.02%
Outro
38.18%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
96
3.98M
51.92%
-466.68K
2025Q1
96
3.96M
52.03%
-545.18K
2024Q4
98
3.98M
62.54%
+317.06K
2024Q3
100
3.09M
48.81%
-530.17K
2024Q2
100
3.18M
50.27%
+64.71K
2024Q1
106
2.47M
41.54%
+268.64K
2023Q4
118
2.50M
200.35%
+260.11K
2023Q3
132
888.05K
20.29%
-1.13M
2023Q2
155
960.87K
22.02%
-1.33M
2023Q1
204
1.08M
24.92%
-1.35M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Gilead Sciences Inc
2.21M
28.93%
--
--
Mar 31, 2025
Schornstein (Alexander)
728.11K
9.53%
-44.00K
-5.70%
Dec 19, 2024
The Vanguard Group, Inc.
215.98K
2.83%
+15.53K
+7.74%
Mar 31, 2025
B Group, Inc.
200.00K
2.62%
+149.35K
+294.86%
Mar 31, 2025
Renaissance Technologies LLC
113.31K
1.48%
+18.60K
+19.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
71.97K
0.94%
-484.00
-0.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
47.70K
0.62%
+1.07K
+2.29%
Mar 31, 2025
Monimus Capital Management, LP
42.07K
0.55%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Data
Tipo
Proporção
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
Feb 08, 2024
Merger
12→1
